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Mesenchymal stem cells (MSCs) have been recognized for their ability to differentiate into cells of different
tissues such as bone, cartilage, or adipose tissue, and therefore are of great interest for potential therapeutic strategies.
Adherent, colony-forming, fibroblastic cells were isolated from human bone marrow aspirates, from patients
undergoing knee arthroplasties, and the MSCs phenotype characterized by flow cytometry. Afterward, cells were
seeded onto electrospun polycaprolactone nanofiber meshes and cultured in a multichamber flow perfusion bioreactor
to determine their ability to produce cartilagineous extracellular matrix. Results indicate that the flow perfusion
bioreactor increased the chondrogenic differentiation of hBM-MSCs, as confirmed either by morphological and
RT-PCR analysis. Cartilage-related genes such as aggrecan, collagen type II, and Sox9 were expressed. ECM
deposition was also detected by histological procedures. Collagen type II was present in the samples, as well as
collagen type I. Despite no statistically significant values being obtained for gene expression, the other results
support the choice of the bioreactor for this type of culture.
Introduction
Due to the epidemiological importance and the high social
costs of joint diseases, cartilage engineering holds remarkable
potential in orthopedic surgery as an alternative to current
surgical methods. Traditional implantable materials frequently
fail its biofunction, due to implant loosening, inflammation,
infection, rejection, wear debris, and tissue inflammation or
infection.1 Tissue engineering (TE) can provide the answers to
many of these problems. One of the challenges of TE is to mimic
the natural extracellular matrix (ECM) of connective tissues,
including cartilage. Nanoscale is very important in this approach,
as the ECM substratum that interacts with cells includes fibrils
at submicrometer level.2 The electrospinning process has been
used to produce nanofibrous scaffolds that can mimic a tissue’s
ECM by imitating its fibrils morphology and distribution.3 These
nanofibrous structures present many advantages, such as high
specific surface area for cell attachment, higher microporous
structure and a 3D microenvironment for cell-cell and cell-
biomaterial contact.1,4 In the past few years, nanomaterials and
nanofibers have been explored as new functional structures for
tissue regeneration in bone,5 cartilage,6 veins, or nerves.7 Some
materials intended for cartilage TE have been produced using
electrospinning of several synthetic and natural materials, such
as PCL,8 PLGA,9 chitosan-based materials,10 or starch-based
materials.11
Cartilage is an avascular tissue composed of chondrocytes
entrapped in an ECM rich in proteoglycans and collagens.12
The low self-regeneration potential of cartilage is due to the
absence of vascular networks and progenitor cells in the tissue,
as well as the nonmobility of chondrocytes in the dense ECM.13
Chondrocytes have been used to generate engineered cartilage
tissue,11,14 and are usually isolated from articular cartilage
tissues. Stem cells are also commonly proposed for cartilage
TE. Chondrocytes are developmentally derived from stem
cells.15 Compared with adult chondrocytes, stem cells are easier
to obtain and manipulate, as they can undergo several passages
before loosening their differentiation potential.16 Mesenchymal
stem cells (MSCs) can be isolated from several tissues, including
bone marrow,17 fat tissue,18 or synovium.19 Selecting the ideal
source of cells for a cartilage TE approach is a demanding and
challenging task, as there are numerous options. Additionally,
the choice of the scaffold is very important. A recent study
showed dissimilar chondrogenic differentiation behavior of
MSCs derived from different tissues, namely, human embryonic
stem cells, bone marrow, and adipose tissue. Additionally, their
behavior also differs among the tested silk and chitosan
scaffolds.16
Dynamic culture systems or bioreactors have been widely
studied for cartilage TE approaches.20-22 Results often show
that they enhance ECM formation when compared with static
cultures. In some bioreactor studies for cartilage TE approaches,
low levels of shear stress were used successfully, as they
promoted good mass transfer properties.23 As chondrocytes are
surrounded by an environment influenced by mechanical forces,
it is logical that the formation of cartilagineous tissue is also
heavily influenced by the environment. Therefore, if cells are
surrounded by an appropriated environment and they have
access to the correct levels of nutrients, it is believed that they
will act like native chondrocytes and secrete ECM.23
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In a recent work using a bovine articular chondrocytes model,
we showed that polycaprolactone (PCL) and SPCL (starch-
compounded PCL) nanofiber meshes are suitable for cartilage
TE.11 In that study, we used a high initial concentration of
bovine articular chondrocytes and cultured the nanofiber meshes
in a lab rotator bioreactor. The results were encouraging, but
from that work, several other questions were raised, namely,
the aspects involved in the future application of this model in
human therapies. In that study a high number of cells were used,
which most of the time are not readily available for clinical
application. The dynamic culture system used in that previous
study did not allow the creation of a controlled environment
for the culture of the constructs, and it is important to obtain a
preimplant with similar characteristics to the native cartilage.
Finally, when going to the clinic, the access to articular
chondrocytes is more limited than it is for MSCs. Having all
these issues in mind, we designed this study to validate if,
starting from low seeding densities of human bone marrow-
derived MSCs in PCL nanofiber meshes cultured in an in-house
developed multichamber flow perfusion bioreactor (PT Patent
No. 104155; European patent pending24), we could induce
chondrogenic differentiation of the MSCs and consequent ECM
deposition. Also, we aimed to determine whether the ECM
deposition would result in cartilage-like tissue, whose charac-
teristics would resemble native articular cartilage.
Materials and Methods
1. Nanofiber Meshes Processing. A polymeric solution of PCL
(PCL 787, TONE polymer, Union Carbide Chemical and Plastics
Division, Bound Brook, NJ, with 80 kDa), at the concentration of 17%
(w/v), was prepared by dissolving the polymer into an organic solvent
mixture of chloroform/dimethylformamide (70:30; Sigma-Aldrich,
U.S.A.). The polymeric solution was placed into a syringe, which is
coupled to a syringe pump (model KDS100, KD Scientific, U.S.A.)
for flow rate control. A blunted metallic needle with an internal diameter
of 0.8 mm was attached to the syringe. A grounded aluminum foil was
used as the fiber mesh collector. A high voltage of 9 kV was applied
to the needle tip to generate the electric field; a needle tip-to-collector
distance of 20 cm and the flow rate of 1.0 mL/h were established. The
applied voltage was maintained at 9 kV. All the experiments were
performed at room temperature and the conditions were optimized for
the production of PCL nanofiber meshes. The produced PCL nanofiber
meshes presented a thickness between 40-60 µm, 70-80% of porosity,
determined by nCT (data not shown) and an average pore size of 2.7
µm. For more details on the PCL nanofiber meshes, please refer to
Guimara˜es et al., 2010.25 After collection, nanofiber meshes were cut
into 1 cm2 squares.
A clamping system to fixate the produced nanofiber meshes in the
multichamber flow perfusion bioreactor (PT Patent No. 104155;
European patent pending24) had to be assembled. The meshes were
fixated in between two silicon rings, which were then clamped with
nylon stitches.25 Using this clamping system, the available surface of
the nanofiber meshes to be cultured in the bioreactor was a circle of 5
mm in diameter. For the static cultures, the referred 1 cm2 squares were
used. The membranes were then sterilized under UV light for 1 h on
each side.
2. Isolation of hBM-MSCs. hBM-MSCs were isolated from bone-
marrow aspirates collected under informed consent from patients
undergoing knee arthroplasties in Hospital de S. Marcos, Braga,
Portugal. Samples were collected from a 55 year old female donor,
isolated, expanded, and frozen in several passages. Briefly, during the
surgery, bone marrow was collected to a container with R-MEM
medium (Invitrogen/12000-063), supplemented with antibiotic/anti-
mycotic solution (Gibco/15240062) and 5000 units of heparin (Sigma/
H3393) and maintained in ice until the isolation procedure. Aspirates
were homogenized, diluted in PBS (Sigma/P4417; 1:1), and incubated
for 5 min at room temperature. Then, bone marrow was diluted in lyses
buffer (1:10) and left under agitation for 10 min. Lyses buffer was
prepared with 10 mM of Tris-HCl (Sigma/T3253), 1.21 g of Tris Base
(Sigma/T1503), and 8.3 g of NH4Cl (Merck/1011455000) in 1 L of
distilled water. Afterward, the suspension was centrifuged at 1200 rpm
for 15 min at room temperature. Cells were resuspended in R-MEM
medium, supplemented with antibiotic/antimycotic solution and 20%
FBS (Biochrom/BSC0115/0943k). Cell suspension was filtered for
disposal of debris, using 100 and 70 µm Cell Strainer (BD Falcon/
352360 and BD Falcon/352350). Cells were counted and plated at a
density of 4.7 × 103 cells/cm2. Cells were expanded in the referred
culture medium until passage 5 and then used for seeding the nanofiber
meshes.
3. Flow-Cytometry Analysis. To evaluate cell-surface marker
expression, cultured cells were incubated for 20 min at 4 °C with
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated
monoclonal antibodies specific for human markers associated with
mesenchymal and hematopoietic lineages. The antibodies used were
CD29, CD34, CD45, CD73, CD90, CD105, and CD116. All the
antibodies were purchased from BD Pharmingen. The samples were
analyzed on a FACS Calibur (BD Biosciences).
4. hBM-MSCs Culture on the Multichamber Flow Perfusion
Bioreactor. hBM-MSCs were detached from the culture flasks by
treatment with trypsin/EDTA solution (Invitrogen/25300-062). Cells
were counted and a cell suspension of 200.000 cells/nanofiber mesh
was prepared to seed each of the nanofiber meshes. Cell seeding was
performed using the “drop” method. The seeding method has been
described previously in more detail by our group, in Guimara˜es et al.,
2010.25 Briefly, each scaffold was seeded with a 10 µL drop of R-MEM
culture medium containing 200.000 cells, in 24-well plates. Afterward,
the constructs were maintained at 37 °C and 5% CO2, during 4 h in an
incubator to allow cell attachment to the scaffolds. After this time
period, culture medium was added to each culture well and left in the
incubator for 24 h. The constructs were then transferred to the
bioreactor.
This is the first work reporting the use of the multichamber bioreactor
designed by our group. The bioreactor has currently a PT patent, and
the European patent is under submission. For detailed information,
please refer to Costa et al., 2010.24 Briefly, the bioreactor apparatus is
composed of a central part with 20 individual culture chambers, with
a diameter of 8 mm each, and two lids attached to the central part.
These lids form a common inlet and outlet of medium. These chambers
were designed in a way that allows the circulation of the culture medium
through them and assures the even distribution of it between the several
flow chambers. For bioreactor cultures, 20 constructs were transferred
for the apparatus and placed one in each chamber. A flow velocity of
70 µL/min/nanofiber mesh was established. The bioreactor apparatus
herein used can be observed in Figure 1. The clamping system has
been previously reported also by a work in our group by Guimara˜es
et al., 2010.25
Figure 1. Multichamber flow perfusion bioreactor (PT Patent No.
104155; European patent pending24) assembled and the culture
system inside the incubator.
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Another set of 20 constructs was transferred to new culture plates
and maintained in static conditions to be used as control. Chondrogenic
differentiation medium consisting of R-MEM supplemented with
antibiotic/antimycotic solution, ITS liquid media supplement (Sigma/
I2521), dexamethasone 1 mM (Sigma/D1756), sodium pyruvate 0.1
M (Sigma/P4562), ascorbate-2-phosphate 17 mM (Sigma/A4544),
L-proline 35 mM (Sigma/P5607), and 1 ng/mL of human recombinant
TGF-!3 (PeproTech/100-36) was used for the 28 days of the experi-
ment. Culture medium in the bioreactor was completely changed every
week (100 mL each time). Control samples were cultured in 24-well
plates and were fed every other day with 1 mL of culture medium.
Samples were collected at every time point, both from the bioreactor
and from static controls. For DNA analysis, two samples were collected
at 14, 21, and 28 days of the experiment. For SEM analysis, 1 sample
was collected on every time point. Three samples at 14, 21, and 28
days were collected for PCR analysis. For histological procedures, one
sample was collected at the end of the experiment. Experiments were
repeated three times.
5. Proliferation Assay (DNA Quantification). Evaluation of cell
proliferation was performed using the PicoGreen dsDNA quantification
Kit (Molecular Probes/P-7589), according to the manufacturer instruc-
tions. Samples from the flow perfusion bioreactor and from the static
control were collected at 14, 21, and 28 days. Triplicates of every time
point were used. A standard curve ranging from 0.0 to 1.5 µg/mL was
established. Fluorescence of both samples and standard curve was read
with an excitation of 485/20 nm and an emission of 528/20 nm. DNA
concentration was extrapolated from the standard curve.
6. Scanning Electron Microscopy (SEM). For SEM analysis, one
hMSCS-nanofiber mesh construct was collected at each time point: 1,
2, 3, and 4 weeks, for each culture condition. They were washed in
sterile PBS and immersed in 3% glutaraldehyde (Sigma/G-5882) at
room temperature for 1 h. Samples were washed in PBS, dehydrated
in increasing ethanol concentrations, and let to dry at room temperature.
Samples were sputter coated with gold and analyzed in a scanning
electron microscope (Model S360, Leica Cambridge, U.K.).
7. RNA Isolation. Three samples were collected from the flow
perfusion bioreactor and from the static control. Samples were washed
in PBS, immersed in TRIzol reagent (Invitrogen/15596-018) and kept
at -80 °C for posterior RNA extraction. To perform the RNA
extraction, samples were taken from the freezer and kept in ice until
complete thawing. Chloroform (Sigma/C-2432) was added; samples
were vigorously agitated for 15 s and then incubated in ice for 15 min.
After that incubation, samples were centrifuged at 13000 rpm, for 15
min, at 4 °C. Afterward, the supernatant was collected for a sterile 1.5
mL tube, and an equivalent volume of isopropanol (Sigma/I-9516) was
added. Samples were incubated at -20 °C overnight to precipitate the
RNA. In the next day, samples were centrifuged at 13000 rpm, for 15
min, at 4 °C. Then, the supernatant was removed and 800 µL of ethanol
70% was added to wash away the isopropanol. The ethanol 70%
solution was prepared from absolute ethanol (Merck/1.00983.2511) and
ultrapure water. The 1.5 mL tubes were agitated vigorously and
centrifuged again, at 9000 rpm for 5 min, at 4 °C. The supernatant
was again removed, and the pellet was left to air-dry. Finally, the pellet
was resuspended in 50 µL of DNase, RNase free water (Gibco/10977-
015). The concentration and purity of the extracted RNA was evaluated
using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Tech-
nologies Inc., U.S.A.).
8. Real Time PCR. The real time PCR procedure used in the present
work consisted of a two-step fluorogenic assay using the SyberGreen
system (Bio-Rad). All the reagents used in this procedure were from
Bio-Rad, following the instructions of the manufacturer. Thermocycler
reaction conditions used were also the mentioned in the kits. In the
first step, RNA was reverse transcribed into cDNA using the iScript
cDNA synthesis kit (1708891). A MiniOpticon real-time PCR detection
system (BioRad Laboratories, U.S.A.) was used to perform the reaction.
Afterward, the cDNA obtained was used as template for the amplifica-
tion of the target genes (aggrecan, collagen type I, II, and X, Sox9 and
Runx2), with the Syber Green Kit (1708884). The number of amplifica-
tion cycles used for every reaction was of 45. GAPDH was used as
reference gene, and the expression of all the target genes was normalized
to the GAPDH expression of that sample. All the primer sequences
were generated using Primer3 software26 and acquired from MWG
Biotech AG, Germany. Primers sequences used are shown in Table 1.
Obtained results were analyzed with CFX Manager Software, version
1.5 (BioRad Laboratories, U.S.A.).
8. Histological Analysis. Samples were collected at the end of the
experiment, included in OCT (Gurr/OCT compound/BDH) and stored
at -20 °C. Sections with 8 µm thickness were placed in microscopy
slides, fixed in a fresh 4% paraformaldehyde (PF) (Sigma/P-6148)
solution in PBS buffer, during 30 min at 4 °C, washed twice in distilled
water, and left overnight to air-dry. Slides were stored at 4 °C until
they were further used for staining procedures. Toluidine blue staining
was performed. Staining solution was prepared by adding 1% of
toluidine blue (Sigma/T-0394) dissolved in distilled water containing
0.5 g of sodium borate, followed by filtering. One drop of this solution
was added to each section for 2-3 s. Then, the sections were rinsed
with distilled water and allowed to air-dry overnight. Sections were
cleared in a xylene substitute (Sigma/A5597) and mounted in Histo
clear (Frilabo/HS200). Safranin O staining was performed by washing
slides in tap water, then immersed in 0.02% fast green (Fluka/44715)
for 3 min. Then, samples were immersed in 1% acetic acid (Panreac/
131008) solution for 30 s. After, slides were immersed in 0.1% safranin
O (Fluka/84120) solution for 5 min. By the end, slides were washed in
tap water and allowed to air-dry. Sections were cleared in xylene and
mounted as previously described.
10. Immunolocalization of Type I and II Collagens. Immunolo-
calization of type I and type II collagens was performed in fixed
sections. Endogenous peroxidase activity was quenched with 0.3%
hydrogen peroxide solution for 30 min. Sections were rinsed in PBS
for 5 min. RTU Vectastain Universal Elite ABC Kit (Vector/VCPK-
7200) was used for antibody incubation according to the instructions
of the manufacturer. Shortly, sections were incubated with primary
antibodies (collagen type I and collagen type II; UNLB/Goat antitype
I collagen 1310-01 and UNLB/Goat antitype II collagen 1320-01)
overnight at 4 °C, in a humidified atmosphere. Incubation was revealed
by using the Peroxidase Substrate Kit DAB (Vector/VCSK-4100).
Slides were washed in water for 5 min and then counterstained with
hematoxylin for nuclei visualization. Finally, slides were mounted in
Histo clear. Controls were performed using normal goat serum instead
of primary antibodies, which was also included in the kit.
11. Statistical Analysis. Statistical analysis was performed using
the SPSS statistic software (Release 15.0.0 for Windows). First, a
Shapiro-Wilk test was used to ascertain the data normality and variance
equality. The normality is strongly rejected and, consequently, non-
parametric tests were used in further comparisons between static and
dynamic culture conditions. A Mann-Whitney U-test was applied to
compare the two independent groups of samples for each variable (i.e.,
DNA quantification and real-time PCR). P values lower than 0.01 were
considered statistically significant in the analysis of the results. A
Kruskal-Wallis test was applied to compare differences in between
the days in each group. P values lower than 0.01 were considered
statistically significant in the analysis of the results.
Table 1. Primer Sequences Used for RT-PCR Proceduresa
gene forward (5′-3′) reverse (5′-3′)
AGC TGAGTCCTCAAGCCTCCTGT TGGTCTGCAGCAGTTGATTC
COL II CGGTGAGAAGGGAGAAGTTG GACCGGTCACTCCAGTAGGA
COL I AGCCAGCAGATCGAGAACAT ACACAGGTCTCACCGGTTTC
COL X CCAGGTCTCGATGGTCCTAA GTCCTCCAACTCCAGGATCA
Runx2 TTCCAGACCAGCAGCACTC CAGCGTCAACACCATCATTC
Sox9 TTCATGAAGATGACCGACGC GTCCAGTCGTAGCCCTTGAG
GAPDH ACAGTCAGCCGCATCTTCTT ACGACCAAATCCGTTGACTC
a AGC ) Agreccan; COL II ) collagen type II; COL I ) collagen type
I; COL X ) collagen type X; Runx2 ) runt-related transcription factor 2;
Sox9 ) Sry-type high mobility group box 9; GAPDH ) glyceraldehyde
3-phosphate dehydrogenase.
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Results
1. Electrospun PCL Nanofiber Meshes. SEM observations
of the produced nanofiber meshes show a random distribution
as expected. This is the most typical morphology obtained in
the electrospinning process, caused by the electric field generated
in the equipment (Figure 2). PCL nanofiber meshes were
composed by nanofibers with diameters in the submicrometer
range, from 0.4 to 1.4 µm.
2. FCM Analysis of the Isolated Cells. Isolated bone
marrow cells were expanded and characterized for specific
surface antigen expression by flow cytometry analysis. hBM-
MSCs were analyzed for hematopoietic marker expression
(CD34 and CD45): isolated cells were negative for these two
markers (not detected, less than 5%). Cells were positive for
CD29 (95%), CD73 (98.3%), CD90 (97.9%), CD105 (85%),
and CD166 (85%) surface markers, which are characteristic of
mesenchymal stem cells. Based in this data we are very
confident that the cell fraction isolated from bone marrow
contains mostly MSCs.
3. DNA Quantification. Results show a higher DNA content
in samples collected from the flow perfusion bioreactor,
compared to the static control conditions, in terms of DNA
concentration (Figure 3). In this condition, DNA contents
decreased a little at 21 days, but then increased by 28 days. In
static conditions samples, there is a continuous decrease of the
DNA contents along the time. To find significant differences
in DNA contents between static and bioreactor culture condi-
tions, the Mann-Whitney U-test was performed. No significant
differences between both culture conditions were found at 14
(p ) 0.18) or 21 days of experiment (p ) 1.00). However,
bioreactor samples displayed a significantly higher DNA
quantification than the static ones at 28 days of experiment
(p ) 0.002).
Concerning statistic differences between the days of culture,
we found none either in static (Kruskal-Wallis test, p ) 0.149)
or in the bioreactor (Kruskal-Wallis test, p ) 0.261).
4. SEM Analysis. SEM observations of the cultured hBM-
MSC in electrospun PCL nanofiber meshes shows some
differences in their morphology along the experiment (Figure
4). At 7 days of culture, samples from the bioreactor showed a
round-shaped morphology, whereas the cells from the static
culture samples presented a fibroblast-like morphology, very
stretched. The round-shaped morphology of cells in the biore-
actor samples is maintained throughout the time course of the
experiment (Figure 4A,C,E,G). In the two last time points, the
cells morphology is not that evident. In Figure 4E and G,
referring to the bioreactor cultures at days 21 and 28, respec-
tively, we can observe that cells form a sheet that covers the
entire mesh surface. Our interpretation of these two figures is
that the production of ECM component and consequent deposi-
tion led to a thin film of cells entrapped in this matrix. Therefore,
there are less “visible” cells, as they are now part of the matrix.
On the other hand, in static cultures we can observe individual
cells, as the matrix production here seems to be delayed, in
comparison to the bioreactor cultures. Cells in static samples
seem to be acquiring the round-shaped morphology along the
time, but by the 28th day of culture they are still not as round-
shaped as the bioreactor (Figure 4G,H).
5. Real-Time PCR. Samples were collected for real-time
PCR at 14, 21, and 28 days of experiment, both from the
bioreactor and static control culture conditions. The aim was
to determine the expression of several cartilage-related genes.
All the tested genes were being expressed. The expression of
the Aggrecan transcript was detected for both culture conditions,
in all time points. The statistical analysis performed, using a
Mann-Whitney U-test, confirmed the absence of significant
difference between culture conditions at 14 (p ) 1.000), 21 (p
) 0.762), and 28 days of experiment (p ) 0.800; Figure 5).
The collagen type II expression was detected, but no significant
difference was found between static and bioreactor culture
conditions on the 14th (p ) 0.233), 21st (p ) 0.413), and 28th
day of experiment (p ) 0.400). The Sox9 transcript is observed
in both culture conditions, following a similar expression pattern.
Statistical analysis of the results for 14 (p ) 1.000), 21 (p )
0.800), and 28 days of culture (p) 0.333) showed no significant
difference between both culture conditions. The expression of
collagen type I showed no significant difference between
bioreactor and static culture conditions found in the 14th (p )
0.563), 21st day (p ) 0.075), or 28th day (p ) 0.071). Collagen
type X is expressed in slightly equal values for both types of
cultures, as well as Runx2. Statistical analysis for collagen type
X confirmed that no significant difference was found between
culture conditions in the 14th (p ) 1), 21st (p ) 0.4), or 28th
day (p ) 1). For Runx2, the same was observed: no significant
difference between the two tested conditions was found in the
21st (p ) 0.400) or in the 28th day of experiment (p ) 1.00).
Figure 2. SEM micrographs of poly(ε-caprolactone) (PCL) nanofiber
meshes processed by electrospinning. Scale bars: 50.0 µm ) 5 cm;
5.0 µm ) 2 cm.
Figure 3. Box plot of the DNA quantification in static and bioreactor
cultures after 14, 21, and 28 days of culture. Data were analyzed by
the nonparametric way of a Mann-Whitney U-test (*p < 0.01, vs
Static).
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6. Histological Staining. Histological sections of electrospun
PCL nanofiber meshes seeded and cultured with hBMSCs, at
28 days of culture in the multichamber bioreactor or in static
conditions were stained for cartilagineous ECM using toluidine
blue and safranin O assays (Figure 6). Toluidine blue staining
detected the presence of glycosaminoglycans in those sections,
and safranin O staining confirmed this observation. It is also
possible to observe a dense concentration of staining on sections
from the bioreactor samples (Figure 6A,B) compared to the static
culture sections on both toluidine blue and safranin O staining.
7. Immunolocalization of Collagen Types I and II. His-
tological sections of electrospun PCL nanofiber meshes cultured
with hBMSCs at 28 days of culture in the multichamber
bioreactor or in static conditions were stained for immunolo-
calization of collagen types I and II (Figure 7). For the bioreactor
cultures, both types of collagens were detected. Collagen type
I stain (Figure 7A) appears to be slightly more clear than the
collagen type II staining (Figure 7B). On the other hand, there
is a heavy unspecific staining on the control sections of both
types of cultures (Figure 7A,D), which may have in part been
due to dye trapped in folded regions of the sections. In static
cultures, a marked staining for collagen type I (Figure 7E) can
be observed, when compared to the collagen type II section
(Figure 7F).
Discussion
Bioreactors are a powerful tool in several areas of TE. In
cartilage TE, they can provide mechanical stimulus to cells, as
well as better access of nutrients, enhancing the production of
ECM. In the present work, we aimed to study the effect of a
new multichamber flow perfusion bioreactor in the chondrogenic
differentiation of hBM-MSCs when seeded onto electrospun
PCL nanofiber meshes. The present work is one of the first
reports that we release concerning the utilization of the
multichamber bioreactor and the present data is starting point
Figure 4. Morphology of hBM-MSCs cultured in electrospun PCL nanofiber meshes, in the flow perfusion bioreactor (A, C, E, G) and in static
control conditions (B, D, F, H) along the time course of the experiment: (A, B) 7 days; (C, D) 14 days; (E, F) 21 days; and (G, H) 28 days.
Different magnifications were used to highlight cell morphology. Scale bars: 100 µm ) 2 cm; 20 µm ) 0.5 cm.
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Figure 6. - Histological section of hBMSCs seeded onto PCL nanofiber meshes for chondrogenic differentiation, at 28 days, from bioreactor
constructs (A, B) and static control cultures (C, D): (A, C) toluidine blue staining; (B, D) safranin O staining. Black arrows show the nuclei of the
cells. White arrows show ECM. Scale bars: 100 µm ) 1 cm; 50 µm ) 2.5 cm.
Figure 5. Bar plots of chondrogenic markers of flow perfusion bioreactor samples and static control conditions normalized for the reference
gene GAPDH, after 14, 21, and 28 days of culture. Data were analyzed with a Mann-Whitney U-test.
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for optimization of the culture conditions used, as several new
questions were raised from the obtained results. It has been
demonstrated that the quality of tissue-engineered cartilage can
be manipulated depending on the type and seeding density of
cells and bioreactor culture conditions.27 Several perfusion
bioreactors have been developed in recent years, aiming to
enhance tissue growth in in vitro constructs,27-29 for example,
for bone,30 dermal tissues,31 and cartilage.32 Dynamic flow
conditions are known to enhance cartilage development com-
pared to static cultures.32-36 For detailed review please refer to
Godara et al., 2008 and Butler et al., 2009.37,38 Fluid flow
enhances nutrient and waste exchange in vitro, improving mass
transport and delivering shear stress within the construct.39 In
perfusion bioreactors, the level of shear stress and of nutrient
transfer can be easily changed by modifying the medium flow
rate, and thus, the quality of the tissue engineered construct can
be improved, depending on the media flow velocity.33 In the
present work, we used a media flow of 70 µL/min/nanofiber
mesh. We based our choice of the flow velocity in the literature.
However, references using nanofiber meshes are scarce, if not
inexistent. Reported flow velocity for 3-D constructs for cartilage
TE range from 0.01 to 5 mL/min.27,28,39,40 We decided to choose
a low flow velocity as a starting point to allow the deposition
of the ECM components. As we performed a low density
seeding, the chosen perfusion velocity would allow, in our
perspective, to provide cells the nutrients and oxygen needed.
We would expect cell proliferation, differentiation and conse-
quent enhanced deposition of ECM components along the time.
As for cell numbers, the amount of cellular DNA varied along
the experiment, being observed a high decrease in static culture
conditions at the 28th day. In this time point, bioreactor samples
displayed a significantly higher DNA quantification than static
(p ) 0.002). It is the fair to state that, in terms of cell
proliferation, the chosen fluid flow was beneficial for the
constructs cultured in the bioreactor, enhancing cell proliferation.
The beneficial effect of directional fluid flow has been demon-
strated by Tarng and co-workers, using periosteal explants
secured onto PCL scaffolds and cultured in spinner flasks. The
authors showed that fluid flow enhanced cell proliferation,
chondrogenic differentiation and cell organization.41
Morphological observation of cells showed some differences
between the two conditions. Cells in the bioreactor samples have
acquired a round-shaped morphology at early stages of culture
(i.e., 7th and 14th day), whereas the cells cultured in static
conditions are stretched and flat until at least the 21st day of
culture. These observations may be related to the fluid flow in
the bioreactor samples. The beneficial effect of the perfusion
can be observed, as the chondrogenic morphology seems to be
highlighted in these samples, whereas in the static ones, the
morphology change can be observed only after 21 days in
culture. TGF-!3 is the essential growth factor for promoting
chondrogenesis both in vivo and in vitro conditions.42 It has
been shown that TGF-!3 induced hBMSCs having increased
Sox9 expression with the presence of collagen type II and
aggrecan.43 Although the cartilage obtained in this study showed
some signs of hypertrophy, induced either by the flow perfusion
or by the utilization of TGF-!3, the conjugation of both factors
may have contributed for the increased chondrogenesis at the
early stages of culture, for the bioreactor samples. Chondro-
genesis at early stages of cultures have been also observed when
culturing chitosan-BMP6 loaded scaffolds with ATDC5 chon-
drocytes cell line in RCMW reactors.44 Additionally, cells
cultured in static cultures showed hypertrophy, contrarily to the
observed in the cultures from the bioreactor. This is not the
case of our results, as the presence of hypertrophy related genes
was detected in both static and dynamic cultures. Hypertrophy
was also observed by Jung and coauthors, when they applied
continuous compressive deformation for 10 or 24 days to PLCL
scaffolds seeded with chondrocytes. These constructs were then
implanted subcutaneously in nude mice. The observations
showed hypertrophic forms in the implants stimulated for 24
days, demonstrating that the proper periodical application of
dynamic compression can enhance GAGs production.45
No statistical differences were found between the expression
levels in the bioreactor samples and the static control cultures.
Cartilage-related genes expression such as aggrecan, collagen
type II, and Sox9, was detected for both conditions. Sox9 is
highly expressed, stimulating the production of these genes. The
high values obtained for standard deviations may be related to
the flow velocity inside the fiber meshes. The dissimilar
geometry of the scaffolds or of the flow perfusion may lead to
different local shear stressed in each sample, even for the same
input flow velocity.39 Thus, the random morphology of the
nanofiber meshes may be influencing the results within the same
replicates. This fact, along with the common inlet and outlet of
the bioreactor, could have resulted in nonuniform flow velocity
Figure 7. Immunolocalization of collagen type I (B, E) and type II (C, F) in electrospun PCL nanofiber meshes, after 28 days of culture in the
bioreactor (A-C) and in static cultures (D-F). Controls of the immunohistochemistry assay (A) were performed with normal horse serum. Scale
bar: 100 µm ) 1 cm.
3234 Biomacromolecules, Vol. 11, No. 12, 2010 Alves da Silva et al.
and therefore could have influenced the ECM deposition and
generate the large standard deviations observed in the experiments.
hBM-MSCs cultured in the bioreactor were able to produce
proteoglycans, as shown by the toluidine blue and safranin O
staining. The presence of proteoglycans was also detected in
the static samples. However, these sections revealed a less
amount of staining when compared to the bioreactor sections.
These stainings, together with the results of RT-PCR for the
expression of aggrecan, indicate the deposition of ECM.
Furthermore, collagen type I and type II present in both types
of samples at 28 days was also detected by immunolocalization,
which is consistent with the RT-PCR results. A different result
was obtained by Li et al., 2008, using PLLA nanofibrous
scaffolds cultured in a rotating wall vessel bioreactor for
cartilage TE. Compared to the constructs obtained in static
cultures, the bioreactor grown constructs produced more total
collagen and GAGs and expressed higher levels of cartilage-
related genes.46
The flow perfusion bioreactor used in this work provides a
continuous flow of media through the construct, enhancing the
mass transfer and the nutrients availability. However, the
mechanical forces can have a detrimental effect in terms of
damaging the neo-tissue formation.40 In the present work, the
bioreactor allowed the proliferation and chondrogenic dif-
ferentiation of hBM-MSCs, but no significant differences were
observed compared to the static cultures. Similar results were
obtained for the chondrogenic differentiation of human adipose
stem cells when cultured in PGA scaffolds using a recirculating
bioreactor.40 The authors showed that the chondrogenic dif-
ferentiation, as well as the ECM formation, was not detrimen-
tally affected by the bioreactor culture. The obtained results do
not allow us to draw any conclusion concerning the enhanced
effect of the bioreactor over chondrogenic differentiation of
hBM-MSCs when seeded onto PCL nanofiber meshes. Some
of the parameters of the experiment here reported have to be
modified, for example, the number of initial cell seeding,
nanofiber mesh structure, or even the fluid flow. We do sustain
that this bioreactor is suitable for this type of culture, and further
optimizations will be performed. The concept of nanofiber
meshes cultured in bioreactors for cartilage TE has been proved
to be applicable to this field, combined with efficient cell loading
and bioreactor technology.46
Conclusions
Overall, we would like to highlight that the new flow
perfusion bioreactor is suitable for culturing hBM-MSCs and
electropun PCL nanofiber meshes. The culture in a flow
perfusion bioreactor supported the attachment, proliferation, and
chondrogenic differentiation of hBM-MSCs. The MSCs were
able to produce ECM on the electrospun PCL nanofiber meshes,
as stated by the staining and imunolocalization results. The
media fluid flow may be influencing these results as well as the
nanofiber mesh random morphology. Therefore, some modifica-
tions in the experimental design should be considered in future
works. The fluid flow should be extensively studied, as there
are scarce literature references using nanofiber meshes in
perfusion bioreactors. In doing this, we will try to improve the
ECM deposition. Additionally, as one of the factors that may
also be influencing the results is the random morphology of
the nanofiber meshes, different production techniques may be
studied to obtain fully controlled morphologies.
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